243 related articles for article (PubMed ID: 18720147)
1. Production and in vitro characterization of solid dosage form incorporating drug nanoparticles.
Basa S; Muniyappan T; Karatgi P; Prabhu R; Pillai R
Drug Dev Ind Pharm; 2008 Nov; 34(11):1209-18. PubMed ID: 18720147
[TBL] [Abstract][Full Text] [Related]
2. Development and characterization of solid oral dosage form incorporating candesartan nanoparticles.
Nekkanti V; Pillai R; Venkateshwarlu V; Harisudhan T
Pharm Dev Technol; 2009; 14(3):290-8. PubMed ID: 19235553
[TBL] [Abstract][Full Text] [Related]
3. Cefdinir nanosuspension for improved oral bioavailability by media milling technique: formulation, characterization and in vitro-in vivo evaluations.
Sawant KK; Patel MH; Patel K
Drug Dev Ind Pharm; 2016; 42(5):758-68. PubMed ID: 26548349
[TBL] [Abstract][Full Text] [Related]
4. A quality-by-design study to develop Nifedipine nanosuspension: examining the relative impact of formulation variables, wet media milling process parameters and excipient variability on drug product quality attributes.
Patel PJ; Gajera BY; Dave RH
Drug Dev Ind Pharm; 2018 Dec; 44(12):1942-1952. PubMed ID: 30027778
[TBL] [Abstract][Full Text] [Related]
5. Development and characterization of nanosuspensions of olmesartan medoxomil for bioavailability enhancement.
Thakkar HP; Patel BV; Thakkar SP
J Pharm Bioallied Sci; 2011 Jul; 3(3):426-34. PubMed ID: 21966165
[TBL] [Abstract][Full Text] [Related]
6. Development of an amorphous nanosuspension by sonoprecipitation-formulation and process optimization using design of experiment methodology.
Gajera BY; Shah DA; Dave RH
Int J Pharm; 2019 Mar; 559():348-359. PubMed ID: 30721724
[TBL] [Abstract][Full Text] [Related]
7. Formulation of dried lignans nanosuspension with high redispersibility to enhance stability, dissolution, and oral bioavailability.
Shen G; Cheng L; Wang LQ; Zhang LH; Shen BD; Liao WB; Li JJ; Zheng J; Xu R; Yuan HL
Chin J Nat Med; 2016 Oct; 14(10):757-768. PubMed ID: 28236405
[TBL] [Abstract][Full Text] [Related]
8. Downstream drug product processing of itraconazole nanosuspension: Factors influencing drug particle size and dissolution from nanosuspension-layered beads.
Parmentier J; Tan EH; Low A; Möschwitzer JP
Int J Pharm; 2017 May; 524(1-2):443-453. PubMed ID: 28400290
[TBL] [Abstract][Full Text] [Related]
9. Nanosuspensions Containing Oridonin/HP-β-Cyclodextrin Inclusion Complexes for Oral Bioavailability Enhancement via Improved Dissolution and Permeability.
Zhang X; Zhang T; Lan Y; Wu B; Shi Z
AAPS PharmSciTech; 2016 Apr; 17(2):400-8. PubMed ID: 26187778
[TBL] [Abstract][Full Text] [Related]
10. Nanosuspension of efavirenz for improved oral bioavailability: formulation optimization, in vitro, in situ and in vivo evaluation.
Patel GV; Patel VB; Pathak A; Rajput SJ
Drug Dev Ind Pharm; 2014 Jan; 40(1):80-91. PubMed ID: 23323843
[TBL] [Abstract][Full Text] [Related]
11. Physicochemical characterization and dissolution study of solid dispersions of ketoconazole with nicotinamide.
Aggarwal AK; Jain S
Chem Pharm Bull (Tokyo); 2011; 59(5):629-38. PubMed ID: 21532202
[TBL] [Abstract][Full Text] [Related]
12. Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine.
Hecq J; Deleers M; Fanara D; Vranckx H; Amighi K
Int J Pharm; 2005 Aug; 299(1-2):167-77. PubMed ID: 15996838
[TBL] [Abstract][Full Text] [Related]
13. Development and characterization of an orodispersible film containing drug nanoparticles.
Shen BD; Shen CY; Yuan XD; Bai JX; Lv QY; Xu H; Dai L; Yu C; Han J; Yuan HL
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1348-56. PubMed ID: 24103635
[TBL] [Abstract][Full Text] [Related]
14. Alternative Manufacturing Concepts for Solid Oral Dosage Forms From Drug Nanosuspensions Using Fluid Dispensing and Forced Drying Technology.
Bonhoeffer B; Kwade A; Juhnke M
J Pharm Sci; 2018 Mar; 107(3):909-921. PubMed ID: 29154900
[TBL] [Abstract][Full Text] [Related]
15. Preparation, characterization and in vivo evaluation of amorphous tacrolimus nanosuspensions produced using CO2-assisted in situ nanoamorphization method.
Wang Y; Han X; Wang J; Wang Y
Int J Pharm; 2016 May; 505(1-2):35-41. PubMed ID: 27034003
[TBL] [Abstract][Full Text] [Related]
16. Preparation of finasteride capsules-loaded drug nanoparticles: formulation, optimization, in vitro, and pharmacokinetic evaluation.
Ahmed TA
Int J Nanomedicine; 2016; 11():515-27. PubMed ID: 26893559
[TBL] [Abstract][Full Text] [Related]
17. Preparation of amorphous indomethacin nanoparticles by aqueous wet bead milling and in situ measurement of their increased saturation solubility.
Colombo M; Minussi C; Orthmann S; Staufenbiel S; Bodmeier R
Eur J Pharm Biopharm; 2018 Apr; 125():159-168. PubMed ID: 29371046
[TBL] [Abstract][Full Text] [Related]
18. Formulation strategy and evaluation of nanocrystal piroxicam orally disintegrating tablets manufacturing by freeze-drying.
Lai F; Pini E; Corrias F; Perricci J; Manconi M; Fadda AM; Sinico C
Int J Pharm; 2014 Jun; 467(1-2):27-33. PubMed ID: 24680963
[TBL] [Abstract][Full Text] [Related]
19. Comparing various techniques to produce micro/nanoparticles for enhancing the dissolution of celecoxib containing PVP.
Homayouni A; Sadeghi F; Varshosaz J; Garekani HA; Nokhodchi A
Eur J Pharm Biopharm; 2014 Sep; 88(1):261-74. PubMed ID: 24952357
[TBL] [Abstract][Full Text] [Related]
20. Formulation, optimization and in vitro-in vivo evaluation of febuxostat nanosuspension.
Ahuja BK; Jena SK; Paidi SK; Bagri S; Suresh S
Int J Pharm; 2015 Jan; 478(2):540-52. PubMed ID: 25490182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
